Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof

Information

  • Patent Grant
  • 11881310
  • Patent Number
    11,881,310
  • Date Filed
    Thursday, March 17, 2022
    2 years ago
  • Date Issued
    Tuesday, January 23, 2024
    3 months ago
Abstract
A Bayesian model for predicting spectacle independence of one or more IOLs based on pre-clinical data (e.g., visual acuity value for one or more defocus values) of an IOL. The Bayesian model is trained to assign appropriate weights for different combinations of defocus values.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

This application is related to systems and methods of selecting, designing and manufacturing intraocular lenses that improve post-surgical spectacle independence in cataract patients.


Description of the Related Art

Retinal image quality of intraocular lenses when implanted in the eye of a patient can be estimated from different metrics obtained from pre-clinical measurements. For example, through focus visual acuity for psuedophakic patients can be predicted from metrics based on various pre-clinical measurements. However, many of the metrics used to predict post-surgical optical performance of intraocular lenses are unable to reliably predict spectacle independence for psuedophakic patients. Spectacle independence is a desired outcome following cataract surgery for most patients. Accordingly, it would be desirable to develop new techniques to reliably predict the spectacle independence for pseudophakic patients receiving different IOLs.


SUMMARY OF THE INVENTION

This application contemplates systems and methods of predicting spectacle independence utilizing pre-clinical data to simulate and predict the expected percentage of patients that will be spectacle independent following cataract surgery with an IOL in which pre-clinical (measured or simulated) data is available. One piece of pre-clinical data that can be used to predict spectacle independence is through-focus visual acuity at one or more defocus positions. For example, it may be possible to predict spectacle independence based on through-focus visual acuity at near distances, such as, for example, near distances greater than or equal to about 25 cm and less than or equal to about 50 cm. However, there is limited information on whether a high peak in through-focus visual acuity at one near distance (e.g., 40 cm) is a better predictor of spectacle independence or whether a flat but lower through-focus visual acuity at a plurality of near distance values between about 25 cm and about 50 cm is a better predictor of spectacle independence. The methods and systems contemplated in this application are based on applying Bayesian models to an initial data set including known spectacle independence information obtained from clinical studies gathering responses to questions in a questionnaire from different patients implanted with different intraocular lenses for which measured or simulated pre-clinical data is available and calculating the probability that a patient would be spectacle independent for a certain value of visual acuity at a certain defocus distance. Since the initial data set is based on a small number of patients (e.g., less than or equal to about 500, less than or equal to about 1000, or less than or equal to about 2000), the prediction of spectacle independence from through-focus visual acuity values at one or more defocus positions can be calculated using “medium data” solutions that operate on medium sized databases. Additionally, machine learning can be employed to appropriately weight and scale the contribution of through-focus visual acuity performance at various defocus distances to spectacle independence.


One innovative aspect of the subject matter disclosed herein is implemented in an optical system configured to select an intraocular lens (IOL) from a plurality of IOLs for manufacture or for implantation into a patient eye, the selected IOL configured or to be manufactured to improve post-surgical spectacle independence outcome for the patient. The optical system comprises a processor configured to execute programmable instructions stored in a non-transitory computer storage medium; and a population database comprising clinical data for a plurality of patients less than or equal to about 5000 implanted with one of the plurality of IOLs, the clinical data comprising information related to spectacle independence for a plurality of values of visual acuity between about −0.2 log MAR and about 1 log MAR at various defocus conditions between about −5D and 0D, wherein the information related to spectacle independence is based on responses of the patients implanted with one of the plurality of IOLs to a questionnaire. The processor is configured to calculate for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least one defocus conditions between about −5D and 0D based on the information related to spectacle independence obtained from the population database; and identify one of the plurality of IOLs having a higher probability of being spectacle independent for manufacture or for implantation into the patient's eye.


The processor can be further configured to calculate for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5D and 0D. The processor can be further configured to assign a weight to the probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5D and 0D. The processor can be configured to execute a machine learning algorithm to determine the weight.


Another innovative aspect of the subject matter disclosed herein can be embodied in an optical system configured to identify an intraocular lens (IOL) that will improve post-surgical spectacle independence. The system comprises a processor configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate a probability of achieving spectacle independence for at least two IOLs based on clinical data providing visual acuity at a first defocus position for the at least two IOLs in a population of patients implanted with one of the at least two IOLs; and identify one of the at least two IOLs having higher probability of achieving spectacle independence.


The processor can be further configured to calculate the probability of achieving spectacle independence for at least two IOLs based on at least one of: clinical data providing visual acuity at a second defocus position for the at least two IOLs in the population; standard deviation of pre-clinical visual acuity for the at least two IOLs at the first or the second defocus positions; clinical data providing minimum readable print size in mm in the population; modulation transfer function (MTF) at one or more frequencies at different distances for different pupil sizes; or area under the modulation transfer function at one or more frequencies at different distances for different pupil sizes.


The first defocus position can be about −2.5D corresponding to a distance of about 40 cm. The second defocus position can have a value between about −5D and about −0.5D. A size of the population can be less than about 1000. The processor can be configured to execute programmable instructions stored in a non-transitory computer storage medium to transmit one or more parameters of the identified IOL to a display device or an IOL manufacturing system.


Yet another innovative aspect of the subject matter disclosed herein is implemented in a system for predicting post-surgical spectacle independence of one or more IOLs, the system comprising a processor configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate a probability of achieving spectacle independence for the one or more IOLs based on clinical data providing visual acuity at one or more defocus position for the one or more IOLs in a population of patients implanted with one of the one or more IOLs.


The processor can be further configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate the probability of achieving spectacle independent based on one or more combinations of visual acuity at at least two or more defocus positions for the one or more IOLs in the population. The processor can be further configured to execute programmable instructions stored in a non-transitory computer storage medium to assign weights to the one or more combinations of visual acuity. The weights can be determined based on a machine learning algorithm.


An innovative aspect of the subject matter disclosed herein is implemented in a method of manufacturing an IOL comprising: receiving one or more parameters of an IOL selected from a plurality of IOLs based on calculating a probability of achieving spectacle independence for the plurality of IOLs from clinical data providing visual acuity at one or more defocus position for the plurality of IOLs in a population of patients implanted with one of the plurality of IOLs; and manufacturing the selected IOL.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present invention may be better understood from the following detailed description when read in conjunction with the accompanying drawings. Such embodiments, which are for illustrative purposes only, depict novel and non-obvious aspects of the invention. The drawings include the following figures:



FIG. 1 is a flowchart illustrating a method of predicting values using Bayesian analysis.



FIG. 2 shows an example method of calculating probability of an event using Bayesian statistics.



FIG. 3A is data from clinical studies for 162 pseudophakic patients that are spectacle independent. FIG. 3B is data from clinical studies for 159 pseudophakic patients that are not spectacle independent.



FIG. 4 is a graph showing a predicted percentage of patients who are spectacle independent obtained using a simple model based on near distance visual acuity.



FIG. 5 illustrates the predicted spectacle independence based on pre-clinical data for different implementations of intraocular lenses.



FIG. 6 is a graphical representation of the elements of computing system for designing or selecting an ophthalmic lens.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent.


As used herein, the terms “about” or “approximately”, when used in reference to a Diopter value of an optical power, mean within plus or minus 0.25 Diopter of the referenced optical power(s). As used herein, the terms “about” or “approximately”, when used in reference to a percentage (%), mean within plus or minus one percent (±1%). As used herein, the terms “about” or “approximately”, when used in reference to a linear dimension (e.g., length, width, thickness, distance, etc.) mean within plus or minus one percent (1%) of the value of the referenced linear dimension.


Spectacle independence is a highly desired outcome following cataract surgery. It is possible to predict through-focus visual acuity (VA) for different implementations of intraocular lenses (IOLs) based on pre-clinical data using mathematical models. Through-focus VA can be predicted for one or more defocus values based on available pre-clinical data for an IOL including but not limited to IOL characteristics such as refractive index of the IOL, radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness. These characteristics can be used in a ray tracing simulation software to predict through-focus MTF, which can predict through-focus VA. IOL designs can be optimized to achieve a desired optical performance based on the predicted values of through-focus VA.


The predicted through-focus VA at one or more defocus values can be based on an output generated by an electronic processor from available pre-clinical data of the IOL input to the electronic processor. The electronic processor can be configured to execute instructions stored on a non-transitory hardware storage medium to generate the output. An example electronic processing system is discussed in detail below with reference to FIG. 6. The through-focus VA at one or more defocus values for an IOL can be measured using a Log MAR chart that can comprise rows of letters. The through-focus VA of an implementation of an IOL is 0 Log MAR if the implementation of the IOL can resolve details as small as 1 minute of visual angle. A series of negative powered lenses can be placed in front of the IOL to simulate near distance vision. In this manner through-focus VA at a plurality of defocus values can be measured to obtain a defocus curve. Without any loss of generality, a defocus value of −2.5 Diopters can correspond to a near distance value of about 40 cm. Defocus values less than −2.5 Diopters correspond to near distance values less than about 40 cm.


This application contemplates systems and methods to predict the expected percentage of patients that will be spectacle independent based when implanted with an IOL whose pre-clinical data is available. The spectacle independence can be estimated using Bayesian analysis. Bayesian analysis is a statistical procedure which combines prior distribution of one or more population parameters before any data is observed with observed information in a sample to obtain an updated probability distribution for the one or more parameters. FIG. 1 illustrates an implementation of the Bayesian analysis. As shown in FIG. 1, the Bayesian analysis begins with a starting model 101. The starting model can be a prior probability density function (pdf) of different hypotheses associated with certain probabilities of being true. New data is collected from a sample of the population as shown in block 103. The new data can be conditional on the different hypotheses. The pdf of the different hypotheses is updated based on the prior pdf and the new data using Bayes' rule shown in block 102. Mathematical Bayes' rule is given by the equation









P
(
A



B

)

=





p
(
B



A

)

*

P


(
A
)




P


(
B
)







When using Bayes analysis to estimate spectacle independence from pre-clinical data, A can correspond to the pdf of different percentages of spectacle independence, and B can correspond to the clinical data that is used to predict spectacle independence.


The clinical data can be a singular value or a multidimensional value. Through-focus VA is an example of a multidimensional value (for example, VA at −3 D, at −2.5 D, at −2 D, . . . , at 0 D of defocus). A singular value can also be used to predict the percentage of spectacle independence. Predicting spectacle independence based on a singular value can be simple and computationally less intensive. Singular values used for predicting spectacle independence can include (i) VA at near distance (e.g., 40 cm), (ii) VA at any other distance, (iii) standard deviation of VA in a certain distance/defocus range which can be a measure of the variability/consistency of VA in the distance/defocus range, (iv) minimum readable print size in mm calculated by predicted angular VA which is converted to stroke width of letters in mm at that distance and taking the minimum value. This corresponds to best distance at which a patient can view small print, (v) modulation transfer function (MTF) at certain spatial frequencies at certain distances and pupil sizes, or (vi) Area under MTF curve at certain distances and pupil sizes.


For singular value metrics B, A can comprise a plurality of probabilities i of spectacle independence, such as 1%, 2%, 3%, . . . , 99%, 100%. The conditional probability of P(A_i|B) can be calculated using Bayes' rule by the equation









P
(
A_i



B

)

=





p
(
B



A_i

)

*

P


(
A_i
)




P


(
B
)







The plurality of probabilities of different percentages of spectacle independence P(A_i) can be determined based on a prior model of spectacle independence, such as having a linear function between 5% and 95%, in the VA range from 0.6 Log MAR to 0 Log MAR at a certain defocus value (e.g., −2.5 D). Bayes analysis can then be used to estimate the probability P(B|A_i), the probability of the set given clinical data assuming spectacle independence A_i through direct calculation from the clinical data as well as the model. P(B) can be considered as a normalization factor.


The method discussed above can be applied for multidimensional values as well. However, some modification and additional techniques may be required when the multidimensional value metric is through-focus VA at different defocus values, since VA at different defocus values may be correlated. Due to the relatively large number of defocus positions, correcting for interaction effects may not possible. In some implementations of Bayesian analysis that employs through-focus VA at different defocus values as the pre-clinical metric, a multidimensional matrix including all possible combinations of VA values at different defocus values may be generated. This matrix can be sampled, for example, in steps of 0.5 D and 0.1 Log MAR. At each such combination there is a pdf for different percentages of spectacle independence. The data added into the matrix could be additive for any VA at any value higher than the given curve for, thus phrasing the probabilities as “having VA of x or higher”.


This method is illustrated in FIG. 2 which has a sample of 20 subjects. Five of the 20 subjects are spectacle independent as shown in block 201 and the remaining fifteen wear spectacles as shown in block 202. Thus, the probability of spectacle independence P(SI) is equal to 5/20 or 25%. Of the five subjects who are spectacle independent, three have a visual acuity greater than 0.1 as shown in block 203 while two have a visual acuity less than 0.1 as shown in block 204. Thus, the conditional probability of having visual acuity greater than 0.1 when being spectacle independent P(VA>0.1|SI) is equal to ⅗ or 60%. Four of the 20 subjects have visual acuity greater than 0.1 as shown in block 205 while sixteen of the 20 subjects have visual acuity less than 0.1 as shown in block 206. Thus, the probability that visual acuity is greater than 0.1 P(VA>0.1) is equal to 4/20 or 20%. Three subjects having visual acuity greater than 0.1 are spectacle independent as shown in block 207 while 1 subject having visual acuity greater than 0.1 is not spectacle independent as shown in block 208. Thus, the probability of being spectacle independent given visual acuity is greater than 0.1 P(SI|VA>0.1) is equal to ¾ or 75%. The probability of being spectacle independent given visual acuity is greater than 0.1 P(SI|VA>0.1) can also be calculated using Bayes' rule as










P
(
SI



VA

>
0.1

)

=





P
(

VA
>
0.1




SI

)

*

P


(
SI
)




P


(

VA
>
0.1

)








which is equal to 75%.


Another example to illustrate the method of determining spectacle independence based on visual acuity is described below. For the sake of simplicity a singular value metric is used to estimate spectacle independence, but the same techniques can be generalized when a multidimensional value is used.


Consider that it is desired to investigate the probability of being spectacle independent if VA at −2.5 D is −0.05 Log MAR. From a clinical data set obtained from observation of 321 subjects, it is found that there are four subjects who are not spectacle independent and have VA at −2.5 D greater than or equal to −0.05 and there are 16 subjects who are spectacle independent and have VA at −2.5 D greater than or equal to −0.05. From the clinical data set, it is further observed that there are 155 subjects who are not spectacle independent and have VA at −2.5 D less than −0.05 and 146 subjects who are spectacle independent and have VA at −2.5 D less than −0.05. FIG. 3A shows the defocus curve for spectacle independent subjects and FIG. 3B shows the defocus curve for subjects who wear spectacles.


Based on the information, the probability of being spectacle independent when VA at −2.5D is greater than or equal to −0.05 P(SI|VA at −2.5D>−0.05)=P(VA at −2.5D>−0.05|SI)*P(SI)/P(VA at −2.5D>−0.05) which is equal to ( 16/162)*(162/321)/( 20/321) which is equal to 80%.



FIG. 4 shows the percentage of spectacle independence for different values of near distance VA obtained using a singular value as described above. It is noted from FIG. 4 that using only near distance VA as a predictor for spectacle independence has an 80% of achieving spectacle independence, regardless of the value of near distance VA of the lens.


It is further noted from FIG. 4 that if VA at all distances is low then the probability of being spectacle independent is about 50%. However, in the clinical data set, there were 102 subjects who are not spectacle independent and have a VA of 0.3 Log MAR or worse, 56 subjects who are not spectacle independent and have VA better than 0.3 Log MAR, 13 subjects who are spectacle independent VA of 0.3 Log MAR or worse, and 144 subjects who are spectacle independent and have VA better than 0.3 Log MAR.


Using Bayes analysis, the probability of being spectacle dependent and having a VA of 0.3 Log MAR or worse P(SD|VA of 0.3 Log MAR or worse)=P(VA of 0.3 Log MAR or worse|SD)*P(SD)/P(VA of 0.3 Log MAR or worse) which is equal to (102/158)*(158/315)/(115/315)=88.7%. Thus, there is an 11.3% chance of being spectacle independent if the VA is 0.3 Log MAR or worse. Thus, the model of predicting spectacle independence based on singular VA value can be updated by combining the two estimates to better predict the chance of being spectacle independent given a certain VA value as described below.


Consider a vector t of length 100 with the probabilities of having 1%, 2%, 3% . . . , 99%, 100% spectacle independent at a certain value of VA. The vector t can be updated according to the example below.


Consider that the vector t has a length of 2 with a 0.5 probability of 80% being spectacle independent and 0.5 probability of 70% being spectacle independent. For VA values above −0.05 we have 4 subjects who wear spectacles and 16 subjects who don't wear spectacles. The probability of being spectacle independent for VA above −0.05, can be calculated using the P(x)=(N!/(x! (N−x)!))*(t∧x)*(1−t)∧(N−x) where N is total number, x is the number of spectacle independent and t is the probability. For the example above, N=20, x=16 and t=0.7 and 0.8. Accordingly, P(x) is equal to 0.13 for t=0.7 and 0.21 for t=0.8. If the initial prior pdf P(A) is [0.5, 0.5], and P(B) is applied as a standard normalization factor, P(A|B)=[0.5*0.13, 0.5*0.21]/(0.5*0.13+0.5*0.21)=0.38 for t=0.7, and 0.62 for t=0.8. In this manner the vector t is updated. A similar technique can be applied for estimating spectacle independence for VA worse than a certain value, and the results combined using a range of methods. A skilled person would understand that it is advantageous to start with a reasonable prior pdf as the posterior probability distribution can skew towards the prior pdf when the number of subjects is low.


The abovementioned technique can also be applied to the multi-dimensional case, where a larger matrix is used and a combination of VA applicable to all defocus positions is selected. In such a case, the sampling may be limited. The sampling limitation can be overcome by using a two-step process, wherein first a coarse sampling is applied, e.g. steps of 0.1 Log MAR. Thereafter, if the VA of interest to test is e.g. 0.12, we combine the two nearby steps, with 80% weight to estimates for VA=0.1 and 20% weight to the estimate with VA=0.2.


The Bayesian analysis method can be expanded to cover more than a binary outcome of spectacle dependent/spectacle independent, and instead describe the probability of never wearing spectacles, of wearing spectacles a little bit of the time, some of the time, or all of the time.


The Bayesian analysis method can be expanded to incorporate other characteristics of the patients, such as age, gender, eye length, pupil size, ethnicity, corneal aberrations, life style or combinations thereof.


The Bayesian analysis method of estimating spectacle independence for different parameters can be incorporated in an IOL design and/or manufacturing process. The parameter space of IOL design allows variation of IOL characteristics such as radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness. These characteristics can be used in a ray tracing simulation software to predict through focus MTF, which can predict VA. Using Bayesian analysis, the probability of spectacle independence can be calculated, and the IOL characteristics optimized such that the highest possible spectacle independence is achieved, in conjunction with other simulated and desired constraints such as distance image quality. Bayesian analysis can also be used to predict how suitable certain treatment techniques, such as making the patients slightly myopic postoperatively can positively affect spectacle independence. Bayesian analysis to estimate spectacle independence can also be used to select an IOL for implantation in a patient that would increase the chance of the patient to be spectacle independent for a variety of tasks such as reading, viewing a smartphone, computer use or combinations thereof.


The spectacle independence of five different implementations of IOLs was predicted based on pre-clinical data based on the Bayesian analysis method described above. To predict spectacle independence, a data set of 321 patients from three different studies was used. The patients were bilaterally implanted with five different implementations of IOLs. Spectacle independence was coded as a binary outcome. Through focus VA was varied in steps of 0.5D between −3D and 0D. A Bayesian model to estimate rate of spectacle independence was developed. The Bayesian model was configured to calculate probability of spectacle independence for VA better than a certain value as well as probability of spectacle dependence for VA worse than a certain value. The Bayesian model was further configured to calculate probability with different combinations of VA at different defocus values. For example, the Bayesian model was configured to (i) calculate probability of VA greater than or worse than a certain value for different single defocus values (e.g., 0D, −0.5D, −1D, −1.5D, −2D, −2.5D, −3D), (ii) calculate probability of VA greater than or worse than a certain value for combinations of two different defocus values (e.g., −3D and −2.5D, −2D and −1D), and (iii) calculate probability of VA greater than or worse than a certain value for combinations of three or more different defocus values. For example, the model was configured to calculate probability of VA greater than or worse than a certain value for combination of seven different defocus values (e.g., 0D, −0.5D, −1D, −1.5D, −2D, −2.5D, and −3D).


The model was trained to combine and weight the different probabilities in order to have outcomes closest to the reported rates of spectacle independence. For example, probability of VA greater than or worse than a certain value for combination of two or more different defocus values that are closer to each other was assigned a higher weight than probability of VA greater than or worse than a certain value for combination of two or more different defocus values that are farther from each other. As another example, probability of VA greater than or worse than a certain value for different defocus values corresponding to near distances between 25 cm and about 40 cm can be assigned a higher weight than VA at other defocus values.


The table below shows the clinically measured percentage spectacle independence for five different IOL implementations Lens 1, Lens 2, Lens 3, Lens 4 and Lens 5. The predicted percentage of spectacle independence using a Bayesian model with multidimensional values as described herein as well as a single through-focus VA at one defocus value is also shown in the table below. The average error and the r∧2 values for the different Bayesian models are also included in the table below.





















Lens
Lens
Lens
Lens
Lens





1
2
3
4
5
Error
r{circumflex over ( )}2























Clinical
93%
76%
66%
62%
 1%




Bayesian Model
95%
70%
74%
51%
 2%
 5%
0.96


with VA at a


plurality of defocus


values


Bayesian Model
87%
71%
59%
36%
15%
12%
0.84


with VA at defocus


value of −3D only


Bayesian Model
71%
73%
66%
38%
13%
12%
0.83


with VA at defocus


value −2.5D only


Bayesian Model
37%
63%
69%
50%
12%
19%
0.45


with VA at defocus


value −2D only


Bayesian Model
36%
44%
60%
59%
34%
26%
0.07


with VA at defocus


value −1.5D only









It is noted from the table above that the Bayesian model based on through-focus VA at a plurality of defocus values as described herein had the highest degree of correlation (r∧2 of 0.96 with the clinically measured spectacle independence.


The benefit of inducing 0.5D of myopia for mini-monovision can also be evaluated using the through focus VA predicted from pre-clinical methods. FIG. 5 shows the through-focus VA based on pre-clinical data for an implementation of an IOL (curve 502) and the same curved shifted by 0.5D (curve 501). Using the Bayesian model discussed herein, it was estimated that an extended range of vision IOL with a spectacle independence rate of 62% could have that rate increased to 83.2% if the patients were made 0.5D myopic.


Referring to FIG. 6, in certain embodiments, a computer system 600 for estimating the probability of being spectacle independent based on available or measured pre-clinical data for an IOL comprises an electronic processor 602 and a computer readable memory 604 coupled to the processor 602. The computer readable memory 604 has stored therein an array of ordered values 608 and sequences of instructions 610 which, when executed by the processor 602, cause the processor 602 to perform certain functions or execute certain modules. For example, a module can be executed that is configured to calculate spectacle independence for one or more IOLs. As another example, a module can be executed that is configured to perform the Bayesian analysis discussed herein and select an IOL that has the highest probability of being spectacle independent. As another example, a module can be executed that is configured to determine an improved or optimal IOL design that improves the probability of being spectacle independent.


The array of ordered values 608 may comprise, for example, one or more ocular dimensions of an eye or plurality of eyes from a database, a desired refractive outcome, parameters of an eye model based on one or more characteristics of at least one eye, and data related to an IOL or set of IOLs such as a power, clinical data providing the number of subjects who are spectacle dependent at one or more VA values, and/or clinical data providing the number of subjects who are spectacle independent at one or more VA values. In some embodiments, the sequence of instructions 610 includes variation of IOL characteristics such as radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness, using these characteristics in a ray tracing simulation software to predict through-focus VA, using Bayesian analysis to predict the probability of spectacle independence, optimize IOL characteristics to increase spectacle independence or select an IOL having the highest probability of spectacle independence.


The computer system 600 may be a general purpose desktop or laptop computer or may comprise hardware specifically configured performing the desired calculations. In some embodiments, the computer system 600 is configured to be electronically coupled to another device such as a phacoemulsification console or one or more instruments for obtaining measurements of an eye or a plurality of eyes. In other embodiments, the computer system 600 is a handheld device that may be adapted to be electronically coupled to one of the devices just listed. In yet other embodiments, the computer system 600 is, or is part of, refractive planner configured to provide one or more suitable intraocular lenses for implantation based on physical, structural, and/or geometric characteristics of an eye, and based on other characteristics of a patient or patient history, such as the age of a patient, medical history, history of ocular procedures, life preferences, and the like.


In certain embodiments, the system 600 includes or is part a phacoemulsification system, laser treatment system, optical diagnostic instrument (e.g, autorefractor, aberrometer, and/or corneal topographer, or the like). For example, the computer readable memory 604 may additionally contain instructions for controlling the handpiece of a phacoemulsification system or similar surgical system. Additionally or alternatively, the computer readable memory 604 may additionally contain instructions for controlling or exchanging data with an autorefractor, aberrometer, tomographer, and/or topographer, or the like.


Rates of spectacle independence can be predicted from through focus VA. It is better to use a combination of VA at many distances than any one distance. Models based on combining clinical data from many studies can offer greater understanding of potential patient outcomes, such as predicting benefits from mini-monovision using EDOF IOLs.


The above presents a description of the best mode contemplated of carrying out the concepts disclosed herein, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use the concepts described herein. The systems, methods and devices disclosed herein are, however, susceptible to modifications and alternate constructions from that discussed above which are fully equivalent. Consequently, it is not the intention to limit the scope of this disclosure to the particular embodiments disclosed. On the contrary, the intention is to cover modifications and alternate constructions coming within the spirit and scope of the present disclosure as generally expressed by the following claims, which particularly point out and distinctly claim the subject matter of the implementations described herein.


Although embodiments have been described and pictured in an example form with a certain degree of particularity, it should be understood that the present disclosure has been made by way of example, and that numerous changes in the details of construction and combination and arrangement of parts and steps may be made without departing from the spirit and scope of the disclosure as set forth in the claims hereinafter.


As used herein, the term “processor” refers broadly to any suitable device, logical block, module, circuit, or combination of elements for executing instructions. For example, the processor 1002 can include any conventional general purpose single- or multi-chip microprocessor such as a Pentium® processor, a MIPS® processor, a Power PC® processor, AMD® processor, ARM processor, or an ALPHA® processor. In addition, the processor 602 can include any conventional special purpose microprocessor such as a digital signal processor. The various illustrative logical blocks, modules, and circuits described in connection with the embodiments disclosed herein can be implemented or performed with a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. Processor 302 can be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.


Computer readable memory 604 can refer to electronic circuitry that allows information, typically computer or digital data, to be stored and retrieved. Computer readable memory 604 can refer to external devices or systems, for example, disk drives or solid state drives. Computer readable memory 1004 can also refer to fast semiconductor storage (chips), for example, Random Access Memory (RAM) or various forms of Read Only Memory (ROM), which are directly connected to the communication bus or the processor 602. Other types of memory include bubble memory and core memory. Computer readable memory 604 can be physical hardware configured to store information in a non-transitory medium.


Methods and processes described herein may be embodied in, and partially or fully automated via, software code modules executed by one or more general and/or special purpose computers. The word “module” can refer to logic embodied in hardware and/or firmware, or to a collection of software instructions, possibly having entry and exit points, written in a programming language, such as, for example, C or C++. A software module may be compiled and linked into an executable program, installed in a dynamically linked library, or may be written in an interpreted programming language such as, for example, BASIC, Perl, or Python. It will be appreciated that software modules may be callable from other modules or from themselves, and/or may be invoked in response to detected events or interrupts. Software instructions may be embedded in firmware, such as an erasable programmable read-only memory (EPROM). It will be further appreciated that hardware modules may comprise connected logic units, such as gates and flip-flops, and/or may comprised programmable units, such as programmable gate arrays, application specific integrated circuits, and/or processors. The modules described herein can be implemented as software modules, but also may be represented in hardware and/or firmware. Moreover, although in some embodiments a module may be separately compiled, in other embodiments a module may represent a subset of instructions of a separately compiled program, and may not have an interface available to other logical program units.


In certain embodiments, code modules may be implemented and/or stored in any type of computer-readable medium or other computer storage device. In some systems, data (and/or metadata) input to the system, data generated by the system, and/or data used by the system can be stored in any type of computer data repository, such as a relational database and/or flat file system. Any of the systems, methods, and processes described herein may include an interface configured to permit interaction with users, operators, other systems, components, programs, and so forth.

Claims
  • 1. An optical system configured to select an intraocular lens (IOL) from a plurality of IOLs for manufacture or for implantation into a patient eye, the selected IOL configured or manufactured to improve post-surgical spectacle independence outcome for the patient, the system comprising: a processor configured to execute programmable instructions stored in a non-transitory computer storage medium; anda population database comprising clinical data for a plurality of patients implanted with one of the plurality of IOLs, the clinical data comprising information related to spectacle independence for a plurality of values of visual acuity between about −0.2 log MAR and about 1 log MAR at various defocus conditions between about −5D and 0D, wherein the information related to spectacle independence is based on responses of the patients implanted with one of the plurality of IOLs to a questionnaire,wherein the processor is configured to: calculate, using Bayesian analysis, for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least one defocus conditions between about −5D and 0D based on the information related to spectacle independence obtained from the population database and measured or calculated pre-clinical data about the plurality of IOLs; andidentify one of the plurality of IOLs having a higher probability of being spectacle independent for manufacture or for implantation into the patient's eye.
  • 2. The optical system of claim 1, wherein the processor is further configured to calculate for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5D and 0D.
  • 3. The optical system of claim 2, wherein the processor is further configured to assign a weight to the probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5D and 0D.
  • 4. The optical system of claim 3, wherein the processor is configured to execute a machine learning algorithm to determine the weight.
  • 5. A method of manufacturing an IOL comprising: receiving one or more parameters of an IOL selected from a plurality of IOLs based on calculating, using Bayesian analysis, a probability of achieving spectacle independence for the plurality of IOLs from clinical data providing visual acuity at one or more defocus position for the plurality of IOLs in a population of patients implanted with one of the plurality of IOLs, the clinical data comprising responses of the patients to a questionnaire, and measured or calculated pre-clinical data about the plurality of IOLs; andmanufacturing the selected IOL.
CROSS REFERENCES TO RELATED APPLICATIONS

This application is a divisional of and claims priority to U.S. patent application Ser. No. 16/205,206, filed Nov. 29, 2018, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/593,162, filed Nov. 30, 2017, which is incorporated herein by reference in its entirety.

US Referenced Citations (351)
Number Name Date Kind
2077092 Broder Apr 1937 A
3305294 Alvarez Feb 1967 A
3367734 Karl et al. Feb 1968 A
3735685 Plummer May 1973 A
4010496 Neefe Mar 1977 A
4056311 Winthrop Nov 1977 A
4077071 Freeman Mar 1978 A
4093361 Erickson et al. Jun 1978 A
4134160 Bayers Jan 1979 A
4162122 Cohen Jul 1979 A
4174543 Kelman Nov 1979 A
4210391 Cohen et al. Jul 1980 A
4249272 Poler Feb 1981 A
4254509 Tennant Mar 1981 A
4254510 Tennant Mar 1981 A
4316293 Bayers Feb 1982 A
4319564 Karickhoff Mar 1982 A
4338005 Cohen Jul 1982 A
4340283 Cohen Jul 1982 A
4370760 Kelman Feb 1983 A
4377873 Reichert, Jr. Mar 1983 A
4402579 Poler Sep 1983 A
4403353 Tennant Sep 1983 A
4404694 Kelman Sep 1983 A
4409691 Levy Oct 1983 A
4424597 Schlegel Jan 1984 A
4437733 Takahashi et al. Mar 1984 A
4446581 Blake May 1984 A
4480340 Shepard Nov 1984 A
4500382 Foster Feb 1985 A
4504982 Burk Mar 1985 A
4551864 Akhavi Nov 1985 A
4556998 Siepser Dec 1985 A
4560383 Leiske Dec 1985 A
4605409 Kelman Aug 1986 A
4605411 Fedorov et al. Aug 1986 A
4629460 Dyer Dec 1986 A
4629462 Feaster Dec 1986 A
4637697 Freeman Jan 1987 A
4642112 Freeman Feb 1987 A
4655565 Freeman Apr 1987 A
4665913 L'Esperance, Jr. May 1987 A
4669466 L'Esperance Jun 1987 A
4673406 Schlegel Jun 1987 A
4676791 LeMaster et al. Jun 1987 A
4676792 Praeger Jun 1987 A
4681102 Bartell Jul 1987 A
4687484 Kaplan Aug 1987 A
4687485 Lim et al. Aug 1987 A
RE32525 Pannu Oct 1987 E
4725277 Bissonette Feb 1988 A
4732148 L'Esperance, Jr. Mar 1988 A
4734095 Siepser Mar 1988 A
4764930 Bille et al. Aug 1988 A
4770172 L'Esperance, Jr. Sep 1988 A
4773414 L'Esperance, Jr. Sep 1988 A
4778462 Grendahl Oct 1988 A
4781717 Grendahl Nov 1988 A
4787903 Grendahl Nov 1988 A
4787904 Severin et al. Nov 1988 A
4795462 Grendahl Jan 1989 A
4798608 Grendahl Jan 1989 A
4798609 Grendahl Jan 1989 A
4828558 Kelman May 1989 A
4834748 McDonald May 1989 A
4863261 Flammer Sep 1989 A
4863539 Lee et al. Sep 1989 A
4898461 Portney Feb 1990 A
4932970 Portney Jun 1990 A
4995714 Cohen Feb 1991 A
4995715 Cohen Feb 1991 A
4997442 Barrett Mar 1991 A
5016977 Baude et al. May 1991 A
5019097 Knight et al. May 1991 A
5042938 Shimozono Aug 1991 A
5047052 Dubroff Sep 1991 A
5054905 Cohen Oct 1991 A
5056908 Cohen Oct 1991 A
5066301 Wiley Nov 1991 A
5071432 Baikoff Dec 1991 A
5078742 Dahan Jan 1992 A
5089023 Swanson Feb 1992 A
5096285 Silberman Mar 1992 A
5108388 Trokel et al. Apr 1992 A
5114220 Baude et al. May 1992 A
5117306 Cohen May 1992 A
5120120 Cohen Jun 1992 A
5121979 Cohen Jun 1992 A
5121980 Cohen Jun 1992 A
5133749 Nordan Jul 1992 A
5144483 Cohen Sep 1992 A
5147395 Willis Sep 1992 A
5147397 Christ et al. Sep 1992 A
5163934 Munnerlyn Nov 1992 A
5173723 Volk et al. Dec 1992 A
5184405 Cress Feb 1993 A
5191187 Kajikawa Mar 1993 A
5197981 Southard Mar 1993 A
5201763 Brady et al. Apr 1993 A
5203790 McDonald Apr 1993 A
5207668 L'Esperance, Jr. May 1993 A
5217491 Vanderbilt Jun 1993 A
5219343 L'Esperance, Jr. Jun 1993 A
5225858 Portney Jul 1993 A
5229797 Futhey et al. Jul 1993 A
5258025 Fedorov et al. Nov 1993 A
5278592 Marie et al. Jan 1994 A
5379110 Matsui et al. Jan 1995 A
5408281 Zhang Apr 1995 A
5433745 Graham et al. Jul 1995 A
5476513 Brady et al. Dec 1995 A
5479220 Komatsu et al. Dec 1995 A
5567365 Weinschenk, III et al. Oct 1996 A
5571177 Deacon et al. Nov 1996 A
5620720 Glick et al. Apr 1997 A
5628796 Suzuki May 1997 A
5646791 Glockler Jul 1997 A
5652638 Roffman et al. Jul 1997 A
5652640 Schneider et al. Jul 1997 A
5691800 Iki et al. Nov 1997 A
5699142 Lee et al. Dec 1997 A
5716403 Tran et al. Feb 1998 A
5748282 Freeman May 1998 A
5760871 Kosoburd et al. Jun 1998 A
5796462 Roffman et al. Aug 1998 A
5801807 Satake et al. Sep 1998 A
5928282 Nigam Jul 1999 A
5968094 Werblin et al. Oct 1999 A
5993438 Juhasz et al. Nov 1999 A
6015435 Valunin et al. Jan 2000 A
6051024 Cumming Apr 2000 A
6126283 Wen et al. Oct 2000 A
6126286 Portney Oct 2000 A
6129759 Chambers Oct 2000 A
6142625 Sawano et al. Nov 2000 A
6179870 Sourdille et al. Jan 2001 B1
6210005 Portney Apr 2001 B1
6235055 Chu May 2001 B1
6241356 Von et al. Jun 2001 B1
6261321 Kellan Jul 2001 B1
6319282 Nishi Nov 2001 B1
6338559 Williams et al. Jan 2002 B1
6419697 Kelman Jul 2002 B1
6457826 Lett Oct 2002 B1
6460997 Frey et al. Oct 2002 B1
6464355 Gil Oct 2002 B1
6474814 Griffin Nov 2002 B1
6488708 Sarfarazi Dec 2002 B2
6491721 Freeman et al. Dec 2002 B2
6497483 Frey et al. Dec 2002 B2
6527389 Portney Mar 2003 B2
6533416 Fermigier et al. Mar 2003 B1
6536899 Fiala Mar 2003 B1
6537317 Steinert et al. Mar 2003 B1
6547822 Lang Apr 2003 B1
6550917 Neal et al. Apr 2003 B1
6554859 Lang et al. Apr 2003 B1
6557992 Dwyer et al. May 2003 B1
6575572 Lai et al. Jun 2003 B2
6598606 Terwee et al. Jul 2003 B2
6609793 Norrby et al. Aug 2003 B2
6705729 Piers et al. Mar 2004 B2
6786603 Altmann Sep 2004 B2
6802605 Cox et al. Oct 2004 B2
6808262 Chapoy et al. Oct 2004 B2
6817714 Altmann Nov 2004 B2
6830332 Piers et al. Dec 2004 B2
6846326 Zadno-Azizi et al. Jan 2005 B2
6851803 Wooley et al. Feb 2005 B2
6899425 Roffman et al. May 2005 B2
6923539 Simpson et al. Aug 2005 B2
6923540 Ye et al. Aug 2005 B2
6986578 Jones Jan 2006 B2
7036931 Lindacher et al. May 2006 B2
7048760 Cumming May 2006 B2
7061693 Zalevsky Jun 2006 B2
7073906 Portney Jul 2006 B1
7137702 Piers et al. Nov 2006 B2
7156516 Morris et al. Jan 2007 B2
7188949 Bandhauer et al. Mar 2007 B2
7281797 Yamaguchi et al. Oct 2007 B2
7287852 Fiala Oct 2007 B2
7293873 Dai et al. Nov 2007 B2
7296893 Dai Nov 2007 B2
7339539 Joannopoulos et al. Mar 2008 B2
7350916 Hong et al. Apr 2008 B2
7365917 Zalevsky Apr 2008 B2
7377640 Piers et al. May 2008 B2
7425068 Koest Sep 2008 B2
7441894 Zhang et al. Oct 2008 B2
7455404 Bandhauer et al. Nov 2008 B2
7455407 Neal et al. Nov 2008 B2
7475986 Dai et al. Jan 2009 B2
7547102 Dai Jun 2009 B2
7615073 Deacon et al. Nov 2009 B2
7616330 Neal et al. Nov 2009 B2
7659971 Warden et al. Feb 2010 B2
7726813 Dai Jun 2010 B2
7784946 LeBlanc Aug 2010 B2
7794497 Brady et al. Sep 2010 B2
7857451 Thibos et al. Dec 2010 B2
7871162 Weeber Jan 2011 B2
7911211 Crain et al. Mar 2011 B2
7931371 Dai Apr 2011 B2
7931374 Dai et al. Apr 2011 B2
7938538 Lu et al. May 2011 B2
7944553 Simpson et al. May 2011 B1
7969585 Neal et al. Jun 2011 B2
8123357 Dai et al. Feb 2012 B2
8382281 Weeber Feb 2013 B2
8480228 Weeber Jul 2013 B2
8596787 Dai Dec 2013 B2
8657445 Olsen Feb 2014 B2
8696119 Van et al. Apr 2014 B2
8740382 Liu et al. Jun 2014 B1
8746882 Canovas et al. Jun 2014 B2
8764822 Harris et al. Jul 2014 B2
8862447 Weeber Oct 2014 B2
9211061 Kasthurirangan et al. Dec 2015 B2
9241627 Steinmueller Jan 2016 B2
9393108 Canovas et al. Jul 2016 B2
9491431 Zhou Nov 2016 B2
9700201 Bex et al. Jul 2017 B2
20010051825 Peterson Dec 2001 A1
20020118337 Perrott et al. Aug 2002 A1
20020173846 Blake et al. Nov 2002 A1
20020196408 Bhalakia et al. Dec 2002 A1
20020196412 Abitbol Dec 2002 A1
20030033013 Callahan et al. Feb 2003 A1
20030053025 Turner et al. Mar 2003 A1
20030076478 Cox Apr 2003 A1
20030163122 Sumiya Aug 2003 A1
20030171808 Phillips Sep 2003 A1
20030189690 Mihashi et al. Oct 2003 A1
20040021825 Richardson Feb 2004 A1
20040054358 Cox et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040085515 Roffman et al. May 2004 A1
20040106992 Lang et al. Jun 2004 A1
20040111153 Woods et al. Jun 2004 A1
20040156014 Piers et al. Aug 2004 A1
20040167622 Sunalp et al. Aug 2004 A1
20040183997 Suzuki Sep 2004 A1
20040260275 Liang et al. Dec 2004 A1
20050024647 Montgomery Feb 2005 A1
20050096226 Stock et al. May 2005 A1
20050122474 Koretz Jun 2005 A1
20050125056 Deacon et al. Jun 2005 A1
20050128432 Altmann Jun 2005 A1
20050203619 Altmann Sep 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060009816 Fang et al. Jan 2006 A1
20060030938 Altmann Feb 2006 A1
20060055877 Yanari Mar 2006 A1
20060066808 Blum et al. Mar 2006 A1
20060068453 Altieri Mar 2006 A1
20060109421 Ye et al. May 2006 A1
20060116763 Simpson Jun 2006 A1
20060116764 Simpson Jun 2006 A1
20060116765 Blake et al. Jun 2006 A1
20060203198 Liang Sep 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060244906 Piers et al. Nov 2006 A1
20060244916 Guillon Nov 2006 A1
20060274268 Andino et al. Dec 2006 A1
20060279699 Liang Dec 2006 A1
20060279700 Liang Dec 2006 A1
20070052920 Stewart et al. Mar 2007 A1
20070052927 Noda et al. Mar 2007 A1
20070129803 Cumming et al. Jun 2007 A1
20070171362 Simpson et al. Jul 2007 A1
20070182924 Hong et al. Aug 2007 A1
20070195265 Dreher et al. Aug 2007 A1
20070268453 Hong et al. Nov 2007 A1
20070285617 Mills et al. Dec 2007 A1
20080018910 Neal et al. Jan 2008 A1
20080030677 Simpson Feb 2008 A1
20080033546 Liang Feb 2008 A1
20080079895 Jubin et al. Apr 2008 A1
20080161913 Brady et al. Jul 2008 A1
20080161914 Brady et al. Jul 2008 A1
20080198331 Azar et al. Aug 2008 A1
20080231809 Haigis Sep 2008 A1
20080269642 Deacon et al. Oct 2008 A1
20080273169 Blum et al. Nov 2008 A1
20080291393 Menezes Nov 2008 A1
20090000628 Somani et al. Jan 2009 A1
20090012609 Geraghty et al. Jan 2009 A1
20090036980 Norrby et al. Feb 2009 A1
20090062911 Bogaert Mar 2009 A1
20090067940 Arai et al. Mar 2009 A1
20090164008 Hong et al. Jun 2009 A1
20090168019 Tuan Jul 2009 A1
20090187242 Weeber et al. Jul 2009 A1
20090210054 Weeber et al. Aug 2009 A1
20090234448 Weeber et al. Sep 2009 A1
20090268155 Weeber Oct 2009 A1
20090275929 Zickler Nov 2009 A1
20090279048 Hong et al. Nov 2009 A1
20090281552 Hiramatsu et al. Nov 2009 A1
20090292354 Gontijo et al. Nov 2009 A1
20090295295 Shannon et al. Dec 2009 A1
20090303465 Clements et al. Dec 2009 A1
20090323020 Zhao et al. Dec 2009 A1
20100016961 Hong et al. Jan 2010 A1
20100016965 Hong et al. Jan 2010 A1
20100082017 Zickler et al. Apr 2010 A1
20100097569 Weeber et al. Apr 2010 A1
20100097619 Ge et al. Apr 2010 A1
20100130888 Deacon et al. May 2010 A1
20100161048 Schaper, Jr. Jun 2010 A1
20100179793 Chernyak et al. Jul 2010 A1
20100220185 Vertoprakhov et al. Sep 2010 A1
20100234833 Dai Sep 2010 A1
20100315589 Portney Dec 2010 A1
20110080562 Izuka et al. Apr 2011 A1
20110149236 Weeber Jun 2011 A1
20110166652 Bogaert et al. Jul 2011 A1
20110205486 Zhao Aug 2011 A1
20110211163 Meuse et al. Sep 2011 A1
20120140166 Zhao Jun 2012 A1
20120168605 Milanovic Jul 2012 A1
20120238904 Manns et al. Sep 2012 A1
20120249955 Sarver et al. Oct 2012 A1
20120310337 Hacker et al. Dec 2012 A1
20130050637 Roffman et al. Feb 2013 A1
20130226294 Van et al. Aug 2013 A1
20130307965 Widman et al. Nov 2013 A1
20130314669 Levin et al. Nov 2013 A1
20130345807 Olsen et al. Dec 2013 A1
20140016088 De et al. Jan 2014 A1
20140081395 Weeber Mar 2014 A1
20140135919 Gontijo et al. May 2014 A1
20140176904 Lai Jun 2014 A1
20140268042 Bor et al. Sep 2014 A1
20140293426 Dobschal Oct 2014 A1
20140320805 Wilzbach et al. Oct 2014 A1
20150062529 Kasthurirangan et al. Mar 2015 A1
20150138350 Videcoq May 2015 A1
20150250583 Rosen et al. Sep 2015 A1
20150320547 Rosen et al. Nov 2015 A1
20150359625 Argal et al. Dec 2015 A1
20150362746 Skudder et al. Dec 2015 A1
20150379348 Whritenor et al. Dec 2015 A1
20160157997 Gerlach et al. Jun 2016 A1
20160161364 Alarcon Heredia et al. Jun 2016 A1
20160299355 Biemold et al. Oct 2016 A1
20160335474 Santos-Villalobos et al. Nov 2016 A1
20170189233 Dewey et al. Jul 2017 A1
20200315848 Rosen et al. Oct 2020 A1
Foreign Referenced Citations (70)
Number Date Country
8107675 Jul 1981 DE
102005022683 Nov 2006 DE
226400 Jun 1987 EP
227357 Jul 1987 EP
0538126 Sep 1996 EP
0810427 Dec 1997 EP
0926531 Jun 1999 EP
957331 Nov 1999 EP
1310267 Jan 2008 EP
2631891 Aug 2013 EP
2653095 Oct 2013 EP
3059575 Aug 2016 EP
2745711 Sep 1997 FR
2433782 Jul 2007 GB
2488802 Sep 2012 GB
2010200915 Sep 2010 JP
8603961 Jul 1986 WO
9222264 Dec 1992 WO
9303409 Feb 1993 WO
9507487 Mar 1995 WO
9856315 Dec 1998 WO
9905499 Feb 1999 WO
0019906 Apr 2000 WO
0111418 Feb 2001 WO
0135868 May 2001 WO
0154569 Aug 2001 WO
0163344 Aug 2001 WO
0182839 Nov 2001 WO
0185016 Nov 2001 WO
0189424 Nov 2001 WO
0221194 Mar 2002 WO
02074210 Sep 2002 WO
03009053 Jan 2003 WO
04028356 Apr 2004 WO
2004034129 Apr 2004 WO
2004053568 Jun 2004 WO
2004079637 Sep 2004 WO
2004090611 Oct 2004 WO
2004096014 Nov 2004 WO
05019906 Mar 2005 WO
2005079546 Sep 2005 WO
06025726 Mar 2006 WO
2006032263 Mar 2006 WO
2006047698 May 2006 WO
06060477 Jun 2006 WO
2006060480 Jun 2006 WO
2007067872 Jun 2007 WO
2007092948 Aug 2007 WO
2007133384 Nov 2007 WO
2007142981 Dec 2007 WO
2008045847 Apr 2008 WO
2008083283 Jul 2008 WO
2009020963 Feb 2009 WO
2009029515 Mar 2009 WO
2009076670 Jun 2009 WO
2009105567 Aug 2009 WO
2009137491 Nov 2009 WO
2010009254 Jan 2010 WO
2010009257 Jan 2010 WO
2010028654 Mar 2010 WO
2012052585 Apr 2012 WO
2012074742 Jun 2012 WO
2012083143 Jun 2012 WO
2012085917 Jun 2012 WO
2012154597 Nov 2012 WO
2012166797 Dec 2012 WO
2015022215 Feb 2015 WO
2016032397 Mar 2016 WO
2016087914 Jun 2016 WO
2016123167 Aug 2016 WO
Non-Patent Literature Citations (71)
Entry
Abelman H., et al. “Tolerance and Nature of Residual Refraction in Symmetric Power Space as Principal Lens Powers and Meridians Change,” Computational and Mathematical Methods in Medicine, Article ID 492383, 2014, vol. 2014, pp. 1-12.
Abrahamsson M., et al., “Impairment of Contrast Sensitivity Function (CSF) as a Measure of Disability Glare,” Investigative Ophthalmology & Visual Science, Jul. 1986, vol. 27 (7), pp. 1131-1136.
Alfonso J.F., et al., “Prospective Study of the Acri.LISA Bifocal Intraocular Lens,” Journal of Cataract Refractive Surgery, Nov. 2007, vol. 33 (11), pp. 1930-1935.
Alio J.L., et al., “Phakic Anterior Chamber Lenses for the Correction of Myopia: A 7-Year Cumulative Analysis of Complications in 263 Cases,” Ophthalmology, Mar. 1999, vol. 106 (3), pp. 458-466.
Apple D.J., et al., “Anterior Chamber Lenses Part 1: Complications and Pathology and a Review of Designs,” Journal of Cataract Refractive Surgery, Mar. 1987, vol. 13 (2), pp. 157-174.
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 36 (1), pp. 21-36.
Apple D.J., et al., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 22 (36), pp. 205-221.
Aslam, T.M., et al., “Development of a Forced Choice Photographic Questionnaire For Photic Phenomena and Its Testing—Repeatability, Reliability and Validity,” Ophthalmologica, Nov.-Dec. 2004, vol. 218 (6), pp. 402-410.
Baikoff G., et al., “Angle-fixated Anterior Chamber Phakic Intraocular Lens for Myopia 7 to −19 Diopters,” Journal of Refractive Surgery, May-Jun. 1998, vol. 14 (3), pp. 282-292.
Baumeister M., et al., “Tilt and Decentration of Spherical and Aspheric Intraocular Lenses: Effect on Higher-Order Aberrations,” Journal of Cataract & Refractive Surgery, 2009, vol. 35 (6), pp. 1006-1012.
Beer J.M., et al., “Lasers' Spectral and Temporal Profile Can Affect Visual Glare Disability,” Aviation, Space, and Environmental Medicine, Dec. 2012, vol. 83 (12), pp. 1135-1144.
Brainard D.H., The Psychophysics Toolbox, Spatial Vision, vol. 10, pp. 433-436.
Brown W.L., “Revisions to Tolerances in Cylinder Axis and in Progressive Addition Lens Power in ANSI Z80.1-2005,” Optometry, 2006, vol. 77 (7), pp. 343-349.
Calatayud A., et al., “Imaging Quality of Multifocal Intraocular Lenses: Automated Assessment Setup,” Ophthalmic and Physiological Optics, Jul. 2013, vol. 33 (4), pp. 420-426.
Canovas C., et al., “Customized Eye Models for Determining Optimized Intraocular Lenses Power,” Biomedical Optics Express, Jun. 1, 2011, vol. 2 (6), pp. 1649-1662.
Canovas C., et al., “Hybrid Adaptive-Optics Visual Simulator,” Optical Letters, Jan. 15, 2010, vol. 35 (2), pp. 196-198.
Cheng X., et al., “Predicting Subjective Judgment of Best Focus with Objective Image Quality Metrics,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 310-321.
CILCO Advertisement Brochure, Oct. 1982, 3 pages.
Cohen A.L., “Practical Design of a Bifocal Hologram Contact Lens or Intraocular Lens,” Applied Optics, Jul. 1, 1992, vol. 31 (19), pp. 3750-3754.
De Almeida M.S., et al., “Different Schematic Eyes and their Accuracy to the in Vivo Eye: A Quantitative Comparison Study,” Brazilian Journal of Physics, Jun. 2007, vol. 37 (2A), 10 pages.
Diffractive Lenses for Extended Depth of Focus and Presbyopic Correction, Presentation from Wavefront Congress held on Feb. 15, 2008, Rochester, New York.
Doskolovich L.L., et al., “Special Diffractive Lenses,” Lens and Optical Systems Design, Apr. 1992, vol. 1780, pp. 393-402.
Einighammer H.J., “The Individual Virtual Eye”, Dissertation, 2008, 157 pages.
Fernandez E.J., et al., “Adaptive Optics Visual Simulator,” Journal of Refractive Surgery, 2002, vol. 18 (5), pp. S634-S638.
Gobbi P.G., et al., “Far and Near Visual Acuity with Multifocal Intraocular Lenses in an Optomechanical Eye Model with Imaging Capability,” Journal of Cataract and Refractive Surgery, 2007, vol. 33 (6), pp. 1082-1094.
Gobbi P.G., et al., “Optomechanical Eye Model with Imaging Capabilities for Objective Evaluation of Intraocular Lenses,” Journal of Cataract and Refractive Surgery, 2006, vol. 32 (4), pp. 643-651.
Guirao A., et al., “Corneal Wave Aberration from Videokeratography: Accuracy And Limitations of the Procedure,” Journal of the Optical Society of America, 2000, vol. 17 (6), pp. 955-965.
Hill W., et al., “Monte Carlo Simulation of Expected Outcomes with the Acrysof Toric Intraocular Lens,” BMC Ophthalmology, Oct. 2008, vol. 8, pp. 22.
Jaeken B., et al., “Peripheral Aberrations in the Human Eye for Different Wavelengths: Off-Axis Chromatic Aberration,” Journal of the Optical Society of America A, Sep. 2011, vol. 28 (9), pp. 1871-1879.
Javitt J.C., et al., “Validity and Reliability of the Cataract TyPE Spec: an Instrument For Measuring Outcomes of Cataract Extraction,” American Journal of Ophthalmology, Aug. 2003, vol. 136 (2), pp. 285-290.
Jendritza B.B., et al., “Wavefront-Guided Excimer Laser Vision Correction after Multifocal IOL Implantation,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 274-279.
Johnson C.A., “Psychophysical Factors that Have Been Applied to Clinical Perimetry,” Vision Research, Sep. 2013, vol. 90, pp. 25-31.
Kim J.H., et al., “The Analysis of Predicted Capsular Bag Diameter using Modified Model of Capsule Measuring Ring in Asians,” Clinical and Experimental Ophthalmology, Apr. 2008, vol. 36 (3), pp. 238-244.
Kim M.J., et al., “Objective Evaluation of Through-Focus Optical Performance of Presbyopia-Correcting Intraocular Lenses Using an Optical Bench System,” Journal of Cataract and Refractive Surgery, 2011, vol. 37 (7), pp. 1305-1312.
Klein S.A., “Optimal Corneal Ablation for Eyes with Arbitrary Hartmann-Shack Aberrations,” Journal of the Optical Society of America A, 1998, vol. 15 (9), pp. 2580-2588.
Lesmes L.A., et al., “Bayesian Adaptive Estimation of the Contrast Sensitivity Function: the Quick CSF Method,” Journal of Vision, Mar. 2010, vol. 10 (3) 17, pp. 1-21.
Liang J., et al., “Objective Measurement Of Wave Aberrations Of The Human Eye With The Use Of A Hartmann-Shack Wave-Front Sensor,” Journal of the Optical Society of America, 1994, vol. 11 (7), pp. 1949-1957.
Liou H.L., et al., “Anatomically Accurate, Finite Model Eye for Optical Modeling,” Journal of Optical Society of America, Aug. 1997, vol. 14 (8), pp. 1684-1695.
Liou H.L., et al., “The Prediction of Spherical Aberration with Schematic Eyes,” Ophthalmic and Physiological Optics, Jan. 1996, vol. 16 (4), pp. 348-354.
Marinho A., “Results are Encouraging for Phakic IOLs, but More Work is needed,” Refractive Surgery, Feb. 2000, p. 12, 15.
Marsack J.D., et al., “Metrics of Optical Quality Derived from Wave Aberrations Predict Visual Performance,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 322-328.
Menapace R., “The Capsular Tension Rings,” Journal of Cataract & Refractive Surgery, Dec. 10, 2008, Chap. 3, pp. 27-44.
Mencucci R., et al., “Clinical outcomes and rotational stability of a 4-haptic toric intraocular lens in myopic eyes,” Journal of Cataract & Refractive Surgery, Sep. 2014, vol. 40 (9), pp. 1479-1487.
Monsoriu J.A., et al., “Devil's Lenses,” Optics Express, Oct. 17, 2007, vol. 15 (21), pp. 13858-13864.
Morlock, R., et al., “Patient-Reported Spectacle Independence Questionnaire (PRSIQ): Development and Validation,” American Journal of Ophthalmology, Jun. 2017, vol. 178, pp. 101-114.
Navarro R., et al., “Accommodation-Dependent Model of the Human Eye with Aspherics,” Journal of the Optical Society of America, Aug. 1985, vol. 2 (8), pp. 1273-1281.
Nio Y.K., et al., “Effect of Intraocular Lens Implantation on Visual Acuity, Contrast Sensitivity, and Depth of Focus,” Journal of Cataract and Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2073-2081.
Norrby S., et al., “Model Eyes for Evaluation of Intraocular Lenses,” Applied Optics, Sep. 7, 2007, vol. 46 (26), pp. 6595-6605.
Olsen T., “Simple Method to Calculate the Surgically Induced Refractive Change,” Journal of Cataract & Refractive Surgery, Mar. 1993, vol. 19 (2), pp. 319-320.
Ortiz, C., et al., “Quantification and Monitoring of Visual Disturbances for patients with cataracts using Halo v1.0 software,” Department of Optics, Laboratory of Vision Sciences and Applications, University of Granada, IWBBIO 2013, Mar. 20, 2013, XP055596332, Proceedings, 8 Pages.
Van der Mooren, M., et al. “Combining in Vitro Test Methods for Measuring Light Scatter in Intraocular Lenses.” Biomedical Optics Express, 2011, vol. 2 (3), pp. 505-510.
Buckhurst P.J., et al., “Tablet App Halometer for the Assessment of Dysphotopsia,” Journal of Cataract and Refractive Surgery, Dec. 2015, vol. 41 (11), pp. 2424-2429.
Peli E., et al., “Appearance of Images Through A Multifocal Intraocular Lens,” Journal of the Optical Society of America, 2001, vol. 18 (2), pp. 302-309.
Piers P.A., et al., “Eye Models for the Prediction of Contrast Vision in Patients with New Intraocular Lens Designs,” Optics Letters, Apr. 1, 2004, vol. 29 (7), pp. 733-735.
Piers P.A., et al., “Theoretical Comparison of Aberration-Correcting Customized and Aspheric Intraocular Lenses,” Journal of Refractive Surgery, Apr. 2007, vol. 23(4), pp. 374-384.
Praeger D.L., “Praeger Technique for the Insertion of the Copeland Radial IOL Posterior Chamber Placement,” Copeland Lens, 1982, 7 pages.
Rosen R.,et al., “A Bayesian Method Using through Focus Visual Acuity to Predict Rates of Spectacle Wear for Pseudophakic patients,” Investigative Ophthalmology & Visual Science, Jul. 2018, vol. 59 (9), pp. 1075, ARVO Annual Meeting Abstract, Retrieved from the Internet: (URL: https://iovs.arvojournals.org/article.aspx?articleid=2693341&resultClick=1).
Siedlecki D., et al., “Radial Gradient index Intraocular Lens: a Theoretical Model,” Journal of Modern Optics, Feb. 20-Mar. 10, 2008, vol. 55 (4-5), pp. 639-647.
Strenn K., et al., “Capsular bag Shrinkage after Implantation of an Open-Loop Silicone Lens and a Poly(methyl methacrylate) Capsule Tension Ring,” Journal of Cataract and Refractive Surgery, Dec. 1997, vol. 23 (10), pp. 1543-1547.
Tehrani M., et al., “Capsule Measuring Ring to Predict Capsular Bag Diameter and Follow its Course after Foldable Intraocular Lens Implantation,” Journal of Cataract Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2127-2134.
Terwee T., et al., “Visualization of the Retinal Image in an Eye Model With Spherical and Aspheric, Diffractive, and Refractive Multifocal Intraocular Lenses,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 223-232.
Van Den Berg T.J., “Analysis of Intraocular Straylight, Especially in Relation to Age,” Optometry and Vision Science, Feb. 1995, vol. 72 (2), pp. 52-59.
Van Meeteren A., “Calculations on the Optical Modulation Transfer Function of the Human Eye for White Light,” Optica Acta, May 1974, vol. 21 (5), pp. 395-412.
Vass C., et al., “Prediction of Pseudophakic Capsular bag Diameter based on Biometric Variables,” Journal of Cataract and Refractive Surgery, Oct. 1999, vol. 25 (10), pp. 1376-1381.
Villegas E.A., et al., “Correlation between Optical and Psychophy, Sical Parameters as a Function of Defocus,” Optometry and Vision Science, Jan. 1, 2002, vol. 79 (1), pp. 60-67.
Vitale S., et al., “The Refractive Status and Vision Profile: A Questionnaire to Measure Vision-Related Quality of Life in Persons with Refractive Error,” Ophthalmology, Aug. 2000, vol. 107 (8), pp. 1529-1539.
Weeber H.A., et al., “Influence of Corneal Aberrations on Dysphotopsia with Multifocal IOLs,” ARVO, 2011, Abstract.
Weeber H.A., et al., “Influence of Corneal Aberrations on Dysphotopsia with Multifocal IOLs,” RD3115, 2011.
Weeber H.A., et al., “Optical and Visual Performance of Patient Populations Implanted with Monofocal and Multifocal IOLs in the Presence of Defocus,” Investigative Ophthalmology & Visual Science, 2010, vol. 51, E-Abstract 5751.
Weeber H.A., et al., “Population-based Visual Acuity in the Presence of Defocus Well Predicted By Classical Theory,” Journal of Biomedical Optics, 2010, vol. 15 (4), pp. 040509.
Weeber H.A., et al., “Theoretical Performance of Intraocular Lenses Correcting Both Spherical and Chromatic Aberration,” Journal of Refractive Surgery, 2012, vol. 28 (1), pp. 48-52.
Related Publications (1)
Number Date Country
20220208379 A1 Jun 2022 US
Provisional Applications (1)
Number Date Country
62593162 Nov 2017 US
Divisions (1)
Number Date Country
Parent 16205206 Nov 2018 US
Child 17655360 US